Lopinavir/ritonavir reduces bupropion plasma concentrations in healthy subjects

Clinical Pharmacology and Therapeutics

Volumn 81, Issue 1, 2007, Pages 69-75

  Hogeland, G W ^a,c   Swindells, S ^b   McNabb, J C ^b   Kashuba, A D M ^a   Yee, G C ^b   Lindley, C M ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c IQVIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; CYTOCHROME P450 2B6; DRUG METABOLITE; GLUCURONOSYLTRANSFERASE; HYDROXYBUPROPION; LOPINAVIR PLUS RITONAVIR; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ERUPTION; DRUG EXPOSURE; DRUG RELEASE; DRUG WITHDRAWAL; ENZYME INDUCTION; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; STEADY STATE; TREATMENT DURATION;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; AREA UNDER CURVE; BUPROPION; DRUG ANTAGONISM; DRUG COMBINATIONS; FEMALE; HALF-LIFE; HIV PROTEASE INHIBITORS; HUMANS; MALE; METABOLIC CLEARANCE RATE; PYRIMIDINONES; RITONAVIR;

EID: 33846039806     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100027     Document Type: Article

References (32)

1. Bing, E.G. et al. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch. Gen. Psychiatry 58, 721-728 (2001).
2. Ciesla, J.A. & Roberts, J.E. Meta-analysis of the relationship between HIV infection and risk for depressive disorders. Am. J. Psychiatry 158, 725-730 (2001).
3. Treisman, G.J. et al. Psychiatric care for patients with HIV infection. The varying perspectives. Psychosomatics 34, 432-439 (1993).
4. Mamary, E.M., Bahrs, D. & Martinez, S. Cigarette smoking and the desire to quit among individuals living with HIV. AIDS Patient Care STDS 16, 39-42 (2002).
5. Dunner, D.L. et al. A prospective safety surveillance study for bupropion sustained-release in the treatment of depression. J. Clin. Psychiatry 59, 366-373 (1998).
6. Johnston, J.A. et al. Relationship between drug exposure and the efficacy and safety of bupropion sustained release for smoking cessation. Nicotine. Tob. Res. 3, 131-140 (2001).
7. Faucette, S.R. et al. Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab. Dispos. 28, 1222-1230 (2000).
8. Hesse, L.M. et al. CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab. Dispos. 28, 1176-1183 (2000).
9. Faucette, S.R., Hawke, R.L., Shord, S.S., Lecluyse, E.L. & Lindley, C.M. Evaluation of the contribution of cytochrome P450 3A4 to human liver microsomal bupropion hydroxylation. Drug Metab. Dispos. 29, 1123-1129 (2001).
10. WELLBUTRIN SR® (bupropion hydrochloride) Sustained-release Tablets, Prescribing information, GlaxoSmithKline, Research Triangle Park, NC, USA (2006).
11. Haynes, K.F.S., Lindley, C., LeCluyse, E., Shord, S. & Hawke, R. Evaluation of Buproprion Hydroxylation as a Probe for Cytochrome P450 2B6 Activity in Cultured Human Hepatocytes, American College of Clinical Pharmacy Savannah, Georgia, April 10, 2002 Poster (2002).
12. US Department of Health and Human Services. AIDSinfo. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Available at: http://aidsinfo.nih.gov/Guidelines/Default.aspx.
13. Hesse, L.M., von Moltke, L.L., Shader, R.I. & Greenblatt, D.J. Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion. Drug Metab. Dispos. 29, 100-102 (2001).
14. NORVIR® (ritonavir capsules) Soft Gelatin, Prescribing information, Abbott Laboratories, North Chicago, IL, USA (2006).
15. Luo, G. et al. CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab. Dispos. 30, 795-804 (2002).
16. Kliewer, S.A., Goodwin, B. & Willson, T.M. The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. Endocr. Rev. 23, 687-702 (2002).
17. KALETRA® (lopinavir/ritonavir) Capsules, Prescribing information, Abbott Laboratories, North Chicago, IL, USA (2005).
18. Gerber, J.G., Rhodes, R.J. & Gal, J. Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19. Chirality 16, 36-44 (2004).
19. Crettol, S. et al. Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. Clin. Pharmacol. Ther. 78, 593-604 (2005).
20. Clarke, S. et al. Absence of opioid withdrawal symptoms in patients receiving methadone and the protease inhibitor lopinavir-ritonavir. Clin. Infect. Dis. 34, 1143-1145 (2002).
21. McCance-Katz, E.F., Rainey, P.M., Friedland, G. & Jatlow, P. The protease inhibitor lopinavir-ritonavir may produce opiate withdrawal in methadone-maintained patients. Clin. Infect. Dis. 37, 476-482 (2003).
22. van der Lee, M.J. et al. Lopinavir/ritonavir reduces lamotrigine plasma concentrations in healthy subjects. Clin. Pharmacol. Ther. 80, 159-168 (2006).
23. Hesse, L.M., Greenblatt, D.J., Von Moltke, L.L. & Court, M.H. Ritonavir has minimal impact on the pharmacokinetic disposition of a single dose of bupropion administered to human volunteers. J. Clin. Pharmacol. 46, 567-576 (2006).
24. Turpeinen, M. et al. Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation. Clin. Pharmacol. Ther. 77, 553-559 (2005).
25. Palovaara, S., Pelkonen, O., Uusitalo, J., Lundgren, S. & Laine, K. Inhibition of cytochrome P450 2B6 activity by hormone replacement therapy and oral contraceptive as measured by bupropion hydroxylation. Clin. Pharmacol. Ther. 74, 326-333 (2003).
26. ZYBAN® (bupropion hydrochloride) Sustained-release Tablets, Prescribing information, GlaxoSmithKline, Research Triangle Park, NC, USA (2006).
27. Hesse, L.M. et al. Effect of bupropion on CYP2B6 and CYP3A4 catalytic activity, immunoreactive protein and mRNA levels in primary human hepatocytes: comparison with rifampicin. J. Pharm. Pharmacol. 55, 1229-1239 (2003).
28. Kumar, G.N. et al. Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: a positive drug-drug interaction. Drug Metab. Dispos. 27, 902-908 (1999).
29. Yeh, R.F. et al. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. J. Acquir. Immune Defic. Syndr 42, 52-60 (2006).
30. Smith, C.M., Faucette, S.R., Wang, H. & LeCluyse, E.L. Modulation of UDP-glucuronosyltransferase 1A1 in primary human hepatocytes by prototypical inducers. J. Biochem. Mol. Toxicol. 19, 96-108 (2005).
31. Faucette, S.R. et al. Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers. Drug. Metab. Dispos. 32, 348-358 (2004).
32. Stewart, J.J. et al. Single-dose pharmacokinetics of bupropion in adolescents: effects of smoking status and gender. J. Clin. Pharmacol. 41, 770-778 (2001).